Comparison of adverse events between cluster and conventional immunotherapy for allergic rhinitis patients with or without asthma : A systematic review and meta-analysis
Copyright © 2019 Elsevier Inc. All rights reserved..
BACKGROUND: Cluster schedule of allergen-specific immunotherapy (AIT) is a cost-effective choice for allergic rhinitis (AR) patients, but its safety has been questioned due to the greater dosages required at each treatment compared with conventional immunotherapy. It remains a question that whether cluster schedule leads to a higher risk of side effects.
OBJECTIVE: This study was designed to update the evidence and investigate whether cluster schedule leads to a higher risk of local adverse reactions (LARs) and systemic adverse reactions (SARs) than cluster schedule does.
METHODS: We searched the Cochrane Central Register of Controlled Trials, EMBASE and Medline thoroughly and included studies comparing cluster and conventional schedules. A meta-analysis of 5 outcomes related to adverse events was performed after bias and heterogeneity assessments. And as a result of language limitations, we considered only articles in Chinese and English.
RESULTS: 5 observational studies and 6 interventional studies were included in the meta-analysis. There were no differences between cluster and conventional schedules when analyzing SARs by the number of patients, delayed SARs, grade 2 SARs and LARs. Analyses of SARs by injection, grade 1 SARs and LARs by injection in observational studies showed that cluster schedule had a lower risk of adverse events than did conventional schedule.
CONCLUSION: Our data suggest that cluster schedule is as safe as or even safer than conventional schedule for AR patients with or without asthma (AS).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
American journal of otolaryngology - 40(2019), 6 vom: 03. Nov., Seite 102269 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiang, Zihan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.04.2020 Date Revised 23.04.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.amjoto.2019.07.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300330820 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300330820 | ||
| 003 | DE-627 | ||
| 005 | 20231225102305.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.amjoto.2019.07.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1001.xml |
| 035 | |a (DE-627)NLM300330820 | ||
| 035 | |a (NLM)31422860 | ||
| 035 | |a (PII)S0196-0709(19)30486-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiang, Zihan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of adverse events between cluster and conventional immunotherapy for allergic rhinitis patients with or without asthma |b A systematic review and meta-analysis |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.04.2020 | ||
| 500 | |a Date Revised 23.04.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Cluster schedule of allergen-specific immunotherapy (AIT) is a cost-effective choice for allergic rhinitis (AR) patients, but its safety has been questioned due to the greater dosages required at each treatment compared with conventional immunotherapy. It remains a question that whether cluster schedule leads to a higher risk of side effects | ||
| 520 | |a OBJECTIVE: This study was designed to update the evidence and investigate whether cluster schedule leads to a higher risk of local adverse reactions (LARs) and systemic adverse reactions (SARs) than cluster schedule does | ||
| 520 | |a METHODS: We searched the Cochrane Central Register of Controlled Trials, EMBASE and Medline thoroughly and included studies comparing cluster and conventional schedules. A meta-analysis of 5 outcomes related to adverse events was performed after bias and heterogeneity assessments. And as a result of language limitations, we considered only articles in Chinese and English | ||
| 520 | |a RESULTS: 5 observational studies and 6 interventional studies were included in the meta-analysis. There were no differences between cluster and conventional schedules when analyzing SARs by the number of patients, delayed SARs, grade 2 SARs and LARs. Analyses of SARs by injection, grade 1 SARs and LARs by injection in observational studies showed that cluster schedule had a lower risk of adverse events than did conventional schedule | ||
| 520 | |a CONCLUSION: Our data suggest that cluster schedule is as safe as or even safer than conventional schedule for AR patients with or without asthma (AS) | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Allergen/therapeutic use | |
| 650 | 4 | |a Allergens/administration and dosage | |
| 650 | 4 | |a Allergens/adverse effects | |
| 650 | 4 | |a Desensitization, immunologic/method | |
| 650 | 4 | |a Desensitization, immunotherapy/adverse effects | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Rhinitis, allergic | |
| 700 | 1 | |a Xiao, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hongting |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Shixi |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Juan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of otolaryngology |d 1993 |g 40(2019), 6 vom: 03. Nov., Seite 102269 |w (DE-627)NLM000961876 |x 1532-818X |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2019 |g number:6 |g day:03 |g month:11 |g pages:102269 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.amjoto.2019.07.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2019 |e 6 |b 03 |c 11 |h 102269 | ||